News & Events
HCRI mourns the loss of Dr. Donald S. Baim
Dr. Baim was founder of HCRI and leading interventional cardiologist
HCRI Enrolls First Patients into DAPT Study
Four-year, Public Health Study to be Conducted Through an Unprecedented Collaboration between Industry, FDA and Academia
HCRI at Connected Health Symposium, October 21-22, at the Boston Park Plaza Hotel & Towers
Please visit HCRI at Table # 12 in the Exhibition Hall
Laura Mauri, M.D., M.S. to present a DAPT Study update at the 2009 TCT Conference
HCRI at TCT 2009, September 21-25, at Moscone Convention Center in San Francisco, CA
HCRI at TCT 2009, September 21-25, at Moscone Convention Center in San Francisco, CA
Please visit HCRI at Booth #2301 in the Exhibition Hall
Microsoft Announces Winners of the 2009 Pharmaceutical and Life Sciences Innovation Awards
AWARDS RECOGNIZE BEST-IN-CLASS: HCRI WINS AWARD FOR CLINICAL DEVELOPMENT
TRANSENDA & HARVARD CLINICAL RESEARCH INSTITUTE ANNOUNCE OFFICE-SMART DEPLOYMENT
HCRI Expands TranSenda Relationship
HCRI Participates in JP Morgan's 2009 Corporate Challenge
On June 25, HCRI was represented by 22 employees in the 33rd annual JP Morgan & Chase Co. Corporate Challenge 3.5 mile race. This is the 5th year that HCRI has participated in the Corporate Challenge. All funds raised will be donated to Camp Harbor View, a summer camp geared toward Boston's youth from at-risk neighborhoods. The company looks forward to the next race in 2010.
HCRI has validated the latest version of InForm™ 4.6 SP1.
HCRI will begin to build trials on InForm™ 4.6 SP1 going forward.
HCRI Business Development to attend American Society of Clinical Oncology (ASCO) annual meeting
David Fontaine, Associate Director, Business Development at HCRI will be attending the ASCO Conference, May 29 to June 2, 2009 in Orlando, Florida
Mr. Fontaine will be meeting with biopharmaceutical Sponsors and Harvard-affiliated hospital oncology Key Opinion Leaders (KOLs) regarding oncology clinical trials.
To schedule a meeting, please contact Mr. Fontaine:
Mr. Fontaine will be meeting with biopharmaceutical Sponsors and Harvard-affiliated hospital oncology Key Opinion Leaders (KOLs) regarding oncology clinical trials.
To schedule a meeting, please contact Mr. Fontaine: